Annual Report Details Generic Nucynta Launch, New Patent Suit, and $500M+ Arbitration Claim

summarizeSummary

Collegium Pharmaceutical's annual report reveals a decline in net income and diluted EPS, alongside the launch of generic Nucynta IR, a new patent infringement lawsuit for Nucynta ER, and a significant $500M+ arbitration claim, posing substantial future risks.

check_boxKey Events

• Generic Nucynta IR Launched, ER Expected

  Hikma Pharmaceuticals USA Inc. launched a generic version of Nucynta IR on February 25, 2026, with a generic Nucynta ER expected in Q1 2026, directly impacting a significant revenue stream for Collegium.

• New Patent Infringement Lawsuit Filed for Nucynta ER

  Gründenthal GMBH filed a patent infringement lawsuit on February 2, 2026, against Collegium and Hikma, alleging that the generic Nucynta ER launch will infringe two patents, adding to existing IP litigation.

• Significant Arbitration Claim Disclosed

  The company is vigorously defending against a Request for Arbitration filed in May 2025 by David Lickrish, seeking compensatory damages estimated to be in excess of $500 million related to the Ironshore Acquisition.

• Mixed Financial Performance for 2025

  Product revenues increased to $780.6 million in 2025 from $631.4 million in 2024, driven by Jornay PM. However, net income decreased to $62.87 million from $69.19 million, and diluted EPS fell to $1.73 from $1.86.

auto_awesomeAnalysis

This annual report provides comprehensive financial results for 2025 and critical updates on competitive and legal challenges. While the company reported strong revenue growth, net income and diluted EPS declined. A significant negative development is the launch of a generic version of Nucynta IR by Hikma Pharmaceuticals on February 25, 2026, with a generic Nucynta ER expected in Q1 2026. This directly impacts a key revenue stream. Further exacerbating this, Gründenthal GMBH filed a new patent infringement lawsuit against Collegium and Hikma on February 2, 2026, related to Nucynta ER. Additionally, the company faces a substantial arbitration claim from David Lickrish (assignee of North Sound Pharmaceuticals) seeking over $500 million in damages. These competitive and legal pressures present considerable risks to future profitability and market position, overshadowing the positive aspects of debt refinancing and improved liquidity.